The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Plasma Protein Therapeutics Market Research Report 2025
Synopsis
Recombinant plasma protein therapeutics market is driven by various factors such as shift from use of plasma-derived proteins to recombinant therapies, rise in awareness about rare disease management and increased focus on investments in rare diseases.
The global Recombinant Plasma Protein Therapeutics market was valued at US$ 92 million in 2023 and is anticipated to reach US$ 136.1 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Recombinant Plasma Protein Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Plasma Protein Therapeutics.
Report Scope
The Recombinant Plasma Protein Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Plasma Protein Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Plasma Protein Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CSL Limited
Takeda
Octapharma
Novo Nordisk A/S
Pfizer
Bioverativ Therapeutics
Aptevo Therapeutics
Pharming Group
Segment by Type
Recombinant Coagulation Factors
Human C1 Esterase Inhibitor
Segment by Application
Hemophilia A
Hemophilia B
Von Willebrand Disease
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Plasma Protein Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Plasma Protein Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Recombinant plasma protein therapeutics market is driven by various factors such as shift from use of plasma-derived proteins to recombinant therapies, rise in awareness about rare disease management and increased focus on investments in rare diseases.
The global Recombinant Plasma Protein Therapeutics market was valued at US$ 92 million in 2023 and is anticipated to reach US$ 136.1 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Recombinant Plasma Protein Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Plasma Protein Therapeutics.
Report Scope
The Recombinant Plasma Protein Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Plasma Protein Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Plasma Protein Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CSL Limited
Takeda
Octapharma
Novo Nordisk A/S
Pfizer
Bioverativ Therapeutics
Aptevo Therapeutics
Pharming Group
Segment by Type
Recombinant Coagulation Factors
Human C1 Esterase Inhibitor
Segment by Application
Hemophilia A
Hemophilia B
Von Willebrand Disease
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Plasma Protein Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Plasma Protein Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Recombinant Plasma Protein Therapeutics Market Overview
1.1 Product Overview and Scope of Recombinant Plasma Protein Therapeutics
1.2 Recombinant Plasma Protein Therapeutics Segment by Type
1.2.1 Global Recombinant Plasma Protein Therapeutics Market Value Comparison by Type (2024-2030)
1.2.2 Recombinant Coagulation Factors
1.2.3 Human C1 Esterase Inhibitor
1.3 Recombinant Plasma Protein Therapeutics Segment by Application
1.3.1 Global Recombinant Plasma Protein Therapeutics Market Value by Application: (2024-2030)
1.3.2 Hemophilia A
1.3.3 Hemophilia B
1.3.4 Von Willebrand Disease
1.4 Global Recombinant Plasma Protein Therapeutics Market Size Estimates and Forecasts
1.4.1 Global Recombinant Plasma Protein Therapeutics Revenue 2019-2030
1.4.2 Global Recombinant Plasma Protein Therapeutics Sales 2019-2030
1.4.3 Global Recombinant Plasma Protein Therapeutics Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Recombinant Plasma Protein Therapeutics Market Competition by Manufacturers
2.1 Global Recombinant Plasma Protein Therapeutics Sales Market Share by Manufacturers (2019-2024)
2.2 Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Recombinant Plasma Protein Therapeutics Average Price by Manufacturers (2019-2024)
2.4 Global Recombinant Plasma Protein Therapeutics Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Plasma Protein Therapeutics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Plasma Protein Therapeutics, Product Type & Application
2.7 Recombinant Plasma Protein Therapeutics Market Competitive Situation and Trends
2.7.1 Recombinant Plasma Protein Therapeutics Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Plasma Protein Therapeutics Players Market Share by Revenue
2.7.3 Global Recombinant Plasma Protein Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Plasma Protein Therapeutics Retrospective Market Scenario by Region
3.1 Global Recombinant Plasma Protein Therapeutics Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Recombinant Plasma Protein Therapeutics Global Recombinant Plasma Protein Therapeutics Sales by Region: 2019-2030
3.2.1 Global Recombinant Plasma Protein Therapeutics Sales by Region: 2019-2024
3.2.2 Global Recombinant Plasma Protein Therapeutics Sales by Region: 2025-2030
3.3 Global Recombinant Plasma Protein Therapeutics Global Recombinant Plasma Protein Therapeutics Revenue by Region: 2019-2030
3.3.1 Global Recombinant Plasma Protein Therapeutics Revenue by Region: 2019-2024
3.3.2 Global Recombinant Plasma Protein Therapeutics Revenue by Region: 2025-2030
3.4 North America Recombinant Plasma Protein Therapeutics Market Facts & Figures by Country
3.4.1 North America Recombinant Plasma Protein Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Recombinant Plasma Protein Therapeutics Sales by Country (2019-2030)
3.4.3 North America Recombinant Plasma Protein Therapeutics Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Recombinant Plasma Protein Therapeutics Market Facts & Figures by Country
3.5.1 Europe Recombinant Plasma Protein Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Recombinant Plasma Protein Therapeutics Sales by Country (2019-2030)
3.5.3 Europe Recombinant Plasma Protein Therapeutics Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Plasma Protein Therapeutics Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Plasma Protein Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Recombinant Plasma Protein Therapeutics Sales by Country (2019-2030)
3.6.3 Asia Pacific Recombinant Plasma Protein Therapeutics Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Recombinant Plasma Protein Therapeutics Market Facts & Figures by Country
3.7.1 Latin America Recombinant Plasma Protein Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Recombinant Plasma Protein Therapeutics Sales by Country (2019-2030)
3.7.3 Latin America Recombinant Plasma Protein Therapeutics Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Plasma Protein Therapeutics Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Plasma Protein Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Recombinant Plasma Protein Therapeutics Sales by Country (2019-2030)
3.8.3 Middle East and Africa Recombinant Plasma Protein Therapeutics Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Recombinant Plasma Protein Therapeutics Sales by Type (2019-2030)
4.1.1 Global Recombinant Plasma Protein Therapeutics Sales by Type (2019-2024)
4.1.2 Global Recombinant Plasma Protein Therapeutics Sales by Type (2025-2030)
4.1.3 Global Recombinant Plasma Protein Therapeutics Sales Market Share by Type (2019-2030)
4.2 Global Recombinant Plasma Protein Therapeutics Revenue by Type (2019-2030)
4.2.1 Global Recombinant Plasma Protein Therapeutics Revenue by Type (2019-2024)
4.2.2 Global Recombinant Plasma Protein Therapeutics Revenue by Type (2025-2030)
4.2.3 Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Type (2019-2030)
4.3 Global Recombinant Plasma Protein Therapeutics Price by Type (2019-2030)
5 Segment by Application
5.1 Global Recombinant Plasma Protein Therapeutics Sales by Application (2019-2030)
5.1.1 Global Recombinant Plasma Protein Therapeutics Sales by Application (2019-2024)
5.1.2 Global Recombinant Plasma Protein Therapeutics Sales by Application (2025-2030)
5.1.3 Global Recombinant Plasma Protein Therapeutics Sales Market Share by Application (2019-2030)
5.2 Global Recombinant Plasma Protein Therapeutics Revenue by Application (2019-2030)
5.2.1 Global Recombinant Plasma Protein Therapeutics Revenue by Application (2019-2024)
5.2.2 Global Recombinant Plasma Protein Therapeutics Revenue by Application (2025-2030)
5.2.3 Global Recombinant Plasma Protein Therapeutics Revenue Market Share by Application (2019-2030)
5.3 Global Recombinant Plasma Protein Therapeutics Price by Application (2019-2030)
6 Key Companies Profiled
6.1 CSL Limited
6.1.1 CSL Limited Corporation Information
6.1.2 CSL Limited Description and Business Overview
6.1.3 CSL Limited Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.1.4 CSL Limited Recombinant Plasma Protein Therapeutics Product Portfolio
6.1.5 CSL Limited Recent Developments/Updates
6.2 Takeda
6.2.1 Takeda Corporation Information
6.2.2 Takeda Description and Business Overview
6.2.3 Takeda Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Takeda Recombinant Plasma Protein Therapeutics Product Portfolio
6.2.5 Takeda Recent Developments/Updates
6.3 Octapharma
6.3.1 Octapharma Corporation Information
6.3.2 Octapharma Description and Business Overview
6.3.3 Octapharma Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Octapharma Recombinant Plasma Protein Therapeutics Product Portfolio
6.3.5 Octapharma Recent Developments/Updates
6.4 Novo Nordisk A/S
6.4.1 Novo Nordisk A/S Corporation Information
6.4.2 Novo Nordisk A/S Description and Business Overview
6.4.3 Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novo Nordisk A/S Recombinant Plasma Protein Therapeutics Product Portfolio
6.4.5 Novo Nordisk A/S Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Pfizer Recombinant Plasma Protein Therapeutics Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Bioverativ Therapeutics
6.6.1 Bioverativ Therapeutics Corporation Information
6.6.2 Bioverativ Therapeutics Description and Business Overview
6.6.3 Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bioverativ Therapeutics Recombinant Plasma Protein Therapeutics Product Portfolio
6.6.5 Bioverativ Therapeutics Recent Developments/Updates
6.7 Aptevo Therapeutics
6.6.1 Aptevo Therapeutics Corporation Information
6.6.2 Aptevo Therapeutics Description and Business Overview
6.6.3 Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Aptevo Therapeutics Recombinant Plasma Protein Therapeutics Product Portfolio
6.7.5 Aptevo Therapeutics Recent Developments/Updates
6.8 Pharming Group
6.8.1 Pharming Group Corporation Information
6.8.2 Pharming Group Description and Business Overview
6.8.3 Pharming Group Recombinant Plasma Protein Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Pharming Group Recombinant Plasma Protein Therapeutics Product Portfolio
6.8.5 Pharming Group Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Plasma Protein Therapeutics Industry Chain Analysis
7.2 Recombinant Plasma Protein Therapeutics Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Plasma Protein Therapeutics Production Mode & Process
7.4 Recombinant Plasma Protein Therapeutics Sales and Marketing
7.4.1 Recombinant Plasma Protein Therapeutics Sales Channels
7.4.2 Recombinant Plasma Protein Therapeutics Distributors
7.5 Recombinant Plasma Protein Therapeutics Customers
8 Recombinant Plasma Protein Therapeutics Market Dynamics
8.1 Recombinant Plasma Protein Therapeutics Industry Trends
8.2 Recombinant Plasma Protein Therapeutics Market Drivers
8.3 Recombinant Plasma Protein Therapeutics Market Challenges
8.4 Recombinant Plasma Protein Therapeutics Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
